Actively Recruiting
Open-label Trial Evaluating VG2025 Injection for Advanced Intrahepatic Cholangiocarcinoma Treatment
Led by Virogin Biotech Ltd. · Updated on 2026-09-22
30
Participants Needed
1
Research Sites
42 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating VG2025, a recombinant human IL1215 dual-regulated oncolytic HSV-1 injection, in a phase IIa clinical trial for advanced intrahepatic cholangiocarcinoma. Previous phase I studies showed good safety without dose-limiting toxicities and suggested early signs of effectiveness, leading to the selection of an appropriate recommended phase II dose for this study. Participants will receive VG2025 through intratumoral injections every four weeks at the recommended phase II dose. This single-group, open-label study focuses on assessing the treatments efficacy and safety in patients with this advanced liver cancer over an extended period. During the trial, participants will undergo regular monitoring for tumor response and disease control up to 36 months, including assessments of progression-free survival, overall survival, immune-related indicators, and correlation with CEA levels. Adverse events and serious adverse events will also be tracked to evaluate safety throughout the study duration.
CONDITIONS
Brief Title
A Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic Cholangiocarcinoma
Research Team
Y
Yinan Shen
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here